A clinical trial has begun which will use stem cell transplants to grow a new immune system for people with untreatable Crohn’s disease – a painful and chronic intestinal disease which affects at least 115,000 people in the UK.
The study, led by Queen Mary University of London and Barts Health NHS Trust, is funded with £2m from a Medical Research Council and National Institute for Health Research partnership, and will be recruiting patients from centres in Cambridge, Edinburgh, Liverpool, London, Nottingham, Oxford and Sheffield. The trial is coordinated through the Clinical Trials Unit at the University of Sheffield.
Crohn’s disease is a long-term condition that causes inflammation of the lining of the digestive system, and results in diarrhoea, abdominal pain, extreme tiredness and other symptoms that significantly affect quality of life.
Current treatments include drugs to reduce inflammation but these have varying results, and surgery is often needed to remove the affected part of the bowel. In extreme cases, after multiple operations over the years, patients may require a final operation to divert the bowel from the anus to an opening in the stomach, called a stoma, where stools are collected in a pouch.
‘We might be able to radically alter the course of the disease’
Chief investigator Professor James Lindsay from Queen Mary’s Blizard Institute and a consultant at Barts Health NHS Trust said: “Despite the introduction of new drugs, there are still many patients who don’t respond, or gradually lose response, to all available treatments. Although surgery with the formation of a stoma may be an option that allows patients to return to normal daily activities, it is not suitable in some and others may not want to consider this approach.
“We’re hoping that by completely resetting the patient’s immune system through a stem cell transplant, we might be able to radically alter the course of the disease. While it may not be a cure, it may allow some patients to finally respond to drugs which previously did not work.”
Helen Bartlett, a Crohn’s disease patient who had stem cell therapy at John Radcliffe Hospital, Oxford, said: “Living with Crohn’s is a daily struggle. You go to the toilet so often, you bleed a lot and it’s incredibly tiring. You also always need to be careful about where you go. I’ve had to get off trains before because there’s been no toilet, and I needed to go there and then.
“I’ve been in and out of hospital for the last twenty years, operation after operation, drug after drug, to try to beat this disease. It’s frustrating, it’s depressing and you just feel so low.
“When offered the stem cell transplant, it was a complete no brainer as I didn’t want to go through yet more failed operations. I cannot describe how much better I feel since the treatment. I still have problems and I’m always going to have problems, but I’m not in that constant pain.”
Giving patients a new immune system
The Latest on: Crohn’s disease
via Google News
The Latest on: Crohn’s disease
Crohn's disease cases on the rise
on May 26, 2019 at 5:00 pm
KOCHI: Inflammatory bowel disease (IBD) is considered rather uncommon in Asia. But according to a survey conducted recently, the disease is becoming more common in India including Kerala. If the ... […]
Nori Health: This tech entrepreneur is using his Crohn’s Disease diagnosis to help people with IBD and IBS
on May 24, 2019 at 4:36 am
Roeland Pater was in his late teens when he was diagnosed with Crohn’s Disease, a form of inflammatory bowel disease (IBD). He ignored it for as long as he could until he was finally hospitalised a ... […]
May is Crohn’s & Colitis Awareness Month in Ascension Parish
on May 22, 2019 at 12:00 pm
According to the proclamation, Crohn’s disease and ulcerative colitis are serious chronic inflammatory diseases of the gastrointestinal tract. Collectively known as inflammatory bowel disease, Crohn’s ... […]
Lilly's Crohn's Disease Candidate Meets Phase II Study Goals
on May 22, 2019 at 7:39 am
Eli Lilly and Company LLY announced that a phase II study evaluating its pipeline candidate mirikizumab in patients with moderately-to-severely active Crohn's disease (“CD”) met the primary ... […]
New Research Reveals High Cost of Care for Inflammatory Bowel Disease Patients in the United States
on May 21, 2019 at 7:30 pm
The findings from "The Cost of Inflammatory Bowel Disease: An Initiative from the Crohn's & Colitis Foundation" were released on advance access in the Inflammatory Bowel Diseases journal today ... […]
Vitamin D fails to prevent postoperative recurrence in certain patients with Crohn’s disease
on May 20, 2019 at 7:51 am
SAN DIEGO — High-dose vitamin D treatment failed to reduce the incidence of postoperative recurrence in patients with Crohn’s disease, according to data presented at Digestive Disease Week. “Vitamin D ... […]
Care coordination solution lowers cost of managing Crohn's disease, study finds
on May 20, 2019 at 4:50 am
When people with Crohn’s disease worked together with their gastroenterologists to detect and address worsening symptoms sooner using a digital care coordination solution, they were more likely to ... […]
Crohn’s Disease Exclusion Diet well-tolerated in children
on May 19, 2019 at 3:17 pm
SAN DIEGO — The Crohn’s Disease Exclusion Diet appeared to be an effective and well-tolerated, first-line therapy for children with mild-to-moderate Crohn’s disease, according to data presented at ... […]
DDW 2019: New Study Shows SonarMD Lowers Cost of Managing Crohn’s Disease
on May 19, 2019 at 10:55 am
When people with Crohn’s disease worked together with their gastroenterologists to detect and address worsening symptoms sooner – using SonarMD’s care coordination solution – they were more likely to ... […]
via Bing News